Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Hedge Funds Are Dumping Revlon Inc (REV)

Page 1 of 2

Hedge funds are not perfect. They have their bad picks just like everyone else. Micron, a stock hedge funds have loved, lost 50% during the last 12 months ending in October 30. Although hedge funds are not perfect, their consensus picks do deliver solid returns, however. Our data show the top 30 S&P 500 stocks among hedge funds at the end of September 2014 yielded an average return of 9.5% in the same time period, vs. a gain of 5.2% for the S&P 500 Index. Because hedge funds have a lot of resources and their consensus picks do well, we pay attention to what they think. In this article, we analyze what the elite funds think of Revlon Inc (NYSE:REV).

Revlon Inc (NYSE:REV) has seen a decrease in support from the world’s most elite money managers of late. Revlon Inc (NYSE:REV) was in 9 hedge funds’ portfolios at the end of September. There were 10 hedge funds in our database with Revlon Inc (NYSE:REV) holdings at the end of the previous quarter. It is important to note that the stock lost 19.78% value during the last quarter, facing a bearish market mood. We will cover hedge funds that maintained positions in Revlon Inc (NYSE:REV), at the end of the third quarter.

In order to find out more about the hedge fund sentiment, we will compare Revlon Inc (NYSE:REV) to other stocks, including American States Water Co (NYSE:AWR), Greif, Inc. (NYSE:GEF), and ABM Industries, Inc. (NYSE:ABM) to get a better sense of its popularity.

Follow Revlon Inc (NYSE:REV)
Trade (NYSE:REV) Now!

According to most traders, hedge funds are assumed to be slow, old financial tools of yesteryear. While there are greater than 8000 funds trading today, we choose to focus on the upper echelon of this group, about 700 funds. Most estimates calculate that this group of people administers the lion’s share of all hedge funds’ total asset base, and by keeping track of their first-class picks, Insider Monkey has identified various investment strategies that have historically beaten the market. Insider Monkey’s small-cap hedge fund strategy outrun the S&P 500 index by 12 percentage points per annum for a decade in their back tests.

Now, let’s view the recent action surrounding Revlon Inc (NYSE:REV).

What does the smart money think about Revlon Inc (NYSE:REV)?

At the end of Q3, a total of 9 of the hedge funds tracked by Insider Monkey were long this stock, a decrease of 10% from one quarter earlier. With hedge funds’ positions undergoing their usual ebb and flow, there exists a few noteworthy hedge fund managers who were increasing their stakes significantly (or already accumulated large positions).

According to publicly available hedge fund and institutional investor holdings data compiled by Insider Monkey, Renaissance Technologies has the largest position in Revlon Inc (NYSE:REV), worth close to $6.4 million, accounting for less than 0.1% of its total 13F portfolio. Coming in second is Millennium Management, led by Israel Englander, holding a $1.4 million position; the fund has less than 0.1% of its 13F portfolio invested in the stock. Some other peers with similar optimism comprise Peter Muller’s PDT Partners, Peter Rathjens, Bruce Clarke and John Campbell’s Arrowstreet Capital, and Roger Ibbotson’s Zebra Capital Management.

Page 1 of 2

Biotech Insider Alert - $5 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!